ABSTRACT
INTRODUCTION

4
Encapsulated pathogens like S. suis employ CPS to evade host innate immunity (12).
66
CPS is the first exposed layer to the host and is associated with functions of various bacterial 67 components and with the immunogenicity of vaccine strains (13), implying the importance of 68 CPS expression for vaccines against encapsulated pathogens. In fact, it has been reported that 69 once anti-CPS antibodies are produced, they will elicit a strong potential to protect the host 70 from S. suis challenge (14, 15).
71
As T-cell independent antigens, the poor immunogenicity of carbohydrates is one of the 72 main obstacles hindering the development of CPS-based vaccines (13, 16) . It is well known 73 that protein-carbohydrate conjugation is an important strategy to induce long-lasting 74 protection against encapsulated bacteria (16, 17) . However, glycoconjugate vaccines may 
88
Considering that evading innate immunity and invading tissue barriers are the two most 89 important processes during S. suis infection, with the premise of maintaining CPS, we 90 selected four genes including scpA, ssnA, fhb, and ssads to construct a live vaccine strain.
91
These four genes are involved in the evasive properties of the pathogen against host innate 92 immune responses (25) (26) (27) (28) (29) , which are responsible for STSLS induced by the streptococcal 93 inflammatory reaction (30). Among these genes, scpA and fhb help the pathogen elude 94 complement-mediated immune defenses (27, 28) , while ssnA and ssads are inhibitors of 95 neutrophil-mediated immune responses (25, 29) . In addition, deletion of sly, a suilysin 96 encoding gene was also taken into account for live vaccine strain construction; SLY is the 97 only well-characterized S. suis toxin and induces rupture of erythrocytes leading to the 98 release of cellular contents (31); sly was also shown to promote migration of S. suis through 99 the blood brain barrier (32).
100
In this study, all five genes mentioned above were deleted in an outbreak S. suis 2 strain, 101 SC19 (33), to obtain an avirulent, CPS-expressing vaccine candidate. This five-gene deletion 
107
RESULTS
108
Growth ability and CPS expression of 2015033 were unaffected by gene deletion. To generate a fully attenuated live vaccine strain, five virulence-associated genes that play 110 different but important roles were deleted in an outbreak S. suis 2 strain, SC19 (Fig. 1) (Fig. 3D) . These results indicated the invasive ability that facilitates 137 the migration of S. suis across different barriers was dramatically reduced in 2015033.
138
Although 2015033 showed no cytotoxicity, its adhesive capacity to HBMEC was similar to 139 that of SC19 (Fig. 3E ), implying adhesins in 2015033 were well preserved. IgG2a, which remained at high levels until the end of the experiment, while mice injected 162 with phosphate buffered saline (PBS) showed no detectable increases (Fig. 5A ). Meanwhile,
163
there was a significant increase in IgG, IgG1, and IgG2a specific to an isogenic 164 nonencapsulated mutant Δcps2E (Fig. 5B ). Significant Ab titers specific to Δcps2E were also 165 observed post immunization and remained at high levels throughout the experiment (Fig. 5C ).
166
In addition, the IgG1 response was significantly higher than that of IgG2a regardless of the 167 antigen type, suggesting Th2-type bias (Fig. 5) . Abs detection demonstrated that 
258
Taken together, these results indicate that multi-gene deletion may be a promising strategy for 259 the development of vaccines against encapsulated invasive pathogens.
260
MATERIALS AND METHODS
261
Bacterial strains, plasmids and growth conditions. Bacterial strains and plasmids used in 262 this study are listed in Table S1 . Primers used to construct gene-deleting plasmids are listed in streptomycin. All cells were incubated at 37°C with 5% CO 2 .
276
Construction of the five-gene (sly, scpA, ssnA, fhb, and ssads) deletion mutant.
277
Target genes are listed in Table S4 and were deleted by an allelic replacement strategy as 278 previously described (37) . Five recombinant plasmids pSET4s-sly, pSET4s-scpA, 279 pSET4s-ssnA, pSET4s-fhb and pSET4s-ssads were generated. pSET4s-sly was subsequently 280 introduced into S. suis SC19 by electroporation. The sly gene deletion mutant Δsly was 281 selected due to its sensitivity to spectinomycin. The pSET4s-scpA was then introduced into 282 the Δsly mutant to generate a double-gene deletion mutant and additional deletions of ssnA, 283 fhb and ssads were performed sequentially following the protocol described above to 284 generate a five-gene deletion mutant. were rotated moderately at 37 °C. Samples were taken at 1, 2 and 3 h, and the viable bacteria Ab responses specific to SC19, polyvinylchloride 96-well plates were coated with 1 × 10 7
349
CFU of SC19 strain for 24 h at 37 °C and then washed with PBST. The washed plates were 350 blocked with 5% skim milk for 2 h at 37 °C. Mouse sera were diluted in 5% skim milk and 
367
At 24 h post-infection, blood samples were harvested by cardiac puncture. Sera were 368 separated by centrifugation (3000 × g, 5 min). Other experimental operations were performed 369 following the protocol described above. Oxford. Population snapshot of clonal complexes was drawn using eBURST software (10). scpA, ssnA, fhb, and ssads) deletion mutant was determined by PCR using primers listed in 788   Table S3 .
789 Table S1 Information of strains and plasmids used in this study.
790
Table S2
Primers used to amplify the flanking sequence of target genes. 
791
